https://biotechmorning.com/news/argenx-sjogrens-trial-failure Biotech Morning en 2026-10-20T14:12:55.140Z Argenx Just Hit a Wall Nobody Saw Coming https://biotechmorning.com/news/lilly-metis-ai-lnp-delivery-deal Biotech Morning en 2026-10-20T14:12:09.297Z Lilly Just Bet $1.1 Billion That AI Can Solve Biotech's Delivery Problem https://biotechmorning.com/news/merck-kgaa-bio-techne-acquisition-biggest-deal Biotech Morning en 2026-10-20T14:11:21.289Z Merck KGaA Just Made Its Biggest Bet in a Decade. Here's What It Bought. https://biotechmorning.com/news/china-biopharma-technology-export-restrictions Biotech Morning en 2026-10-20T14:10:32.870Z China Just Drew a Line Around Its Best Biotech Secrets https://biotechmorning.com/news/tezepelumab-crossing-eoe-phase-3-results Biotech Morning en 2026-10-20T14:09:51.923Z The Asthma Drug Crashing Dupixent's Biggest Party https://biotechmorning.com/news/eyepoint-wet-amd-double-failure-layoffs Biotech Morning en 2026-10-20T14:09:03.827Z EyePoint's Wet AMD Drug Failed Twice. Then Came the Pink Slips. https://biotechmorning.com/news/dostarlimab-rectal-cancer-fda-approval Biotech Morning en 2026-10-20T14:08:18.776Z The Cancer That Disappeared in Every Single Patient https://biotechmorning.com/news/merck-kgaa-silence-therapeutics-acquisition Biotech Morning en 2026-10-20T14:07:34.760Z Merck KGaA Just Paid $1.3 Billion to Silence a Gene https://biotechmorning.com/news/shionogi-intrabio-2-billion-rare-disease-acquisition-2 Biotech Morning en 2026-10-19T14:12:44.375Z Shionogi Just Bet $2 Billion on a Disease Most People Have Never Heard Of https://biotechmorning.com/news/bitopertin-apollo-epp-trial-results Biotech Morning en 2026-10-19T14:11:57.932Z Roche's Failed Schizophrenia Drug Just Aced a Trial for a Rare Disease https://biotechmorning.com/news/roche-hansoh-second-adc-deal Biotech Morning en 2026-10-19T14:11:08.813Z Roche Just Went Back for Seconds in China https://biotechmorning.com/news/nouscom-135-million-cancer-vaccine Biotech Morning en 2026-10-19T14:10:20.120Z $135 Million to Stop Cancer Before It Starts https://biotechmorning.com/news/viatris-pacira-acquisition-non-opioid-pain Biotech Morning en 2026-10-19T14:09:37.435Z Viatris Just Paid a 45% Premium to Break Up With Generics https://biotechmorning.com/news/gilead-crashes-ibd-party-ulcerative-colitis Biotech Morning en 2026-10-19T14:08:50.559Z Gilead Just Crashed the Biggest Party in Gastroenterology https://biotechmorning.com/news/abbvie-abbv-466-beats-skyrizi-crohns-disease Biotech Morning en 2026-10-19T14:08:07.412Z AbbVie Just Beat Its Own Blockbuster. On Purpose.